Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences. The company will present at the RBC Global Healthcare Conference on May 21, 2025, at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 AM ET.
Both presentations will be available via live webcast through Cidara's investor relations website, with replays accessible for at least 30 days. The company will also engage in one-on-one meetings with investors during these events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CDTX declined 0.36%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences.
Event: RBC Global Healthcare Conference
Date: Wednesday, May 21, 2025
Time: 10:00 AM ET
Event: Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Time: 11:40 AM ET
The live webcast for the presentations can be accessed in the Investors section on the Company’s website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during these events.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) present at the RBC Global Healthcare Conference in 2025?
What is Cidara Therapeutics' (CDTX) main technology platform?
When is Cidara's (CDTX) presentation at the Jefferies Global Healthcare Conference?
How long will the replays of Cidara's (CDTX) conference presentations be available?
